The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Targeted Agent Appears Promising in Inducing Cancer Cell Apoptosis in Chronic Leukemia Model
December 9th 2009Current treatments for chronic lymphocytic leukemia (CLL) can be damaging to the immune system, leaving patients vulnerable to infections, which is the primary cause of death for many patients with CLL. According to a study presented at the 51st Annual American Society of Hematology Meeting, a new oral agent called 17-DMAG may avoid this problem. Mouse models assessing 17-DMAG showed this agent to be highly selective for CLL cells, while having minimal effect on normal immune cells, suggesting the agent leaves the immune system intact.
Dabigatran versus Warfarin in VTE
December 8th 2009Cancer patients are at high risk for venous thromboembolism (VTE), a leading cause of death in patients with cancer. Fixed-dose dabigatran may be a replacement for warfarin in the treatment of VTE, according to results of the large Phase III RE-COVER trial.